Embeddedadvisor
US
APAC
EUROPE
  • Home
  • Insights
  • Whitepaper
  • Conferences
  • Newsletter
  • Subscribe
  • News
  • About us
Go to...
  • Home
  • Insights
  • Whitepaper
  • Conferences
  • Newsletter
  • Subscribe
  • News
  • About us
  • Categories

  • IP Design
  • Telecom
  • Wearables and Sensor
  • Consumer Electronics
  • IoT
  • More
      • Industrial Computing
Go to...
  • Categories

  • IP Design
  • Telecom
  • Wearables/Sensor
  • Consumer Electronics
  • IoT
  • Industrial Computing
×
#

Embedded Advisor Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Embedded Advisor

Subscribe

loading

THANK YOU FOR SUBSCRIBING

  • Home
  • Insights
  • Medical Devices
Editor's Pick(1 - 4 of 8)
left
The Changing Role of CIO in the Biopharmaceutical Industry

Andy Newsom, CIO, CSL Behring

Automation Leading the Change in Healthcare

Rick Schooler, VP & CIO, Orlando Health

Keeping Up with the Latest Medical Trends

Joseph G Seay, Former SVP & CIO, Community Health Systems

Making Healthcare Better Through Mobile Innovation

Bijoy Sagar, Global CIO, Stryker

Innovations that Enhance Public Healthcare

John Kravitz, CIO, Geisinger

Making Digital Health a Primary rather than an Additive Solution

Jennifer Briley Christian, Vice President, Clinical Evidence, IQVIA [NYSE: IQV]

Strong Business- HR Partnerships, Coupled With Technology, Help Drive Talent Agenda

Cindy Carlisle, VP, HR. Commercial Operations, Roche Diagnostics Corporation

Next-Generation Commercial Data Management Systems for Biopharmaceuticals

Ashwin Athri, SVP, Precision for Value

right

Recent Trend and Development in Pharmaceutical Industry

By Richard Hu, Associate Director CMC, Curis, Inc. [NASDAQ: CRIS]

Tweet

Richard Hu, Associate Director CMC, Curis, Inc. [NASDAQ: CRIS]

In our exciting and ever-changing industry, pharmaceutical and biotech companies must continue innovating not only their technologies but also the way they do business. Let’s review the top three trends that are “hot” in the eyes of a formulation scientist.

The first thing that came to mind is the advancement of CRISPR/Cas9, a gene editing technology developed by Professor Zhang at MIT. Inspired by how living cells disable invading viruses, CRISPR (Clustered Regularly Short Palindromic Repeats) technology utilizes Cas9, a nuclease enzyme, to cut DNA strands at a precise location when the target gene is complexed with a guide-RNA. As a result, scientists can disable certain sequence in that gene and understand the function of that particular sequence. Sequentially, CRISPR also enables scientists to add a desired function to the gene by inserting a pre-fabricated sequence. We all know that genes define who we are as life-forms and individuals. There is no doubt that our genes have a profound effect on our health. While still in its infancy, gene editing certainly has the potential to completely transform not only our industry but our world as well. If something can finally bankrupt our social security, I think gene editing will be it.

"For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game"

For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game. In this new hope, scientists are developing drugs that can stimulate our own immune system to recognize and fight cancerous cells. One such advancement is the chimeric antigen receptor (CAR) T-cell technology, in which a patient’s own immune cells are removed, engineered to have the ability to recognize and attack cancerous cells, then infused back to his/her body to fight cancer. While only approved to treat limited types of cancer and may have severe side effects, the approval of Kymriah® and Yescarta® clearly represents the future of personalized medicine. Another trend worth mentioning in immunotherapy is the advancement of checkpoint inhibitor. These drugs are often highly targeted, highly efficient and have relatively low side effects. In recent years, antibody-based checkpoint inhibitors have dramatically improved the management of cancer. To me, developing small molecule version of such inhibitors, which are orally available and going to be much cheaper, is even more exciting.

In the foreseeable future, biopharmaceutical companies, regardless of their sizes, will continue to utilize R&D outsourcing to access innovations and expertise. According to Visiongain, the global drug discovery outsourcing market is expected to exceed $40 billion by 2026. Meanwhile, the tide of outsourcing model is certainly shifting, especially at early stage. R&D work is coming back to the States, while some companies start to run clinical trials in developing countries, often-times looking for treatment-naïve patients. I also sense a strong focus from pharmaceutical companies on partnering with academia. In the past few years, several major pharma companies moved their R&D headquarters into the most congested neighborhoods in Boston, with the intention to put their folks into the proximity of Harvard and MIT. But for God’s sake, put them in the suburb and take a subway to the “Inspiration” when needed. Haven’t they checked out the Boston morning traffic in last twenty years?

Check out: Semiconductor Review

Read Also

Innovations that Enhance Public Healthcare

Innovations that Enhance Public Healthcare

John Kravitz, CIO, Geisinger
Making Digital Health a Primary rather than an Additive Solution

Making Digital Health a Primary rather than an Additive Solution

Jennifer Briley Christian, Vice President, Clinical Evidence, IQVIA [NYSE: IQV]
Strong Business- HR Partnerships, Coupled With Technology, Help Drive Talent Agenda

Strong Business- HR Partnerships, Coupled With Technology, Help Drive Talent Agenda

Cindy Carlisle, VP, HR. Commercial Operations, Roche Diagnostics Corporation
Next-Generation Commercial Data Management Systems for Biopharmaceuticals

Next-Generation Commercial Data Management Systems for Biopharmaceuticals

Ashwin Athri, SVP, Precision for Value

Weekly Brief

loading
Top 10 Medical Devices Design and Solutions Companies - 2019

Medical Devices Special

Featured Vendors

  • ANSYS [NASDAQ:ANSS]: Modeling Human Body with Simulation Software
    ANSYS [NASDAQ:ANSS]: Modeling Human Body with Simulation Software
  • ADM Tronics Unlimited, Inc. [OTC:ADMT]: Transforming Care with Innovative Medical Technologies
    ADM Tronics Unlimited, Inc. [OTC:ADMT]: Transforming Care with Innovative Medical Technologies
  • DFI-ITOX:  High-Performance Medical Computing Devices
    DFI-ITOX: High-Performance Medical Computing Devices
  • OrthoSensor: Advanced Sensor-Assisted Technology for a Balanced Total Knee Replacement
    OrthoSensor: Advanced Sensor-Assisted Technology for a Balanced Total Knee Replacement

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Copyright © 2021 Embedded Advisor. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy Policy.
follow on linkedin follow on twitter
This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

medical-devices.embeddedadvisor.com/cxoinsights/recent-trend-and-development-in-pharmaceutical-industry-nid-453.html